Nobel Prize method uses light to control individual brain cells

In 2026, Karl Deisseroth of Stanford University, Peter Hegemann, and Georg Nagel were awarded the Nobel Prize in Physiology or Medicine for developing optogenetics. The technique uses light-sensitive proteins called channelrhodopsins. These proteins are introduced into specific neurons using genetic methods. Researchers, and eventually clinicians, can then activate or silence those neurons with a pulse of light.

Why optogenetics is different

The brain contains billions of neurons of dozens of different types. Existing methods to influence brain cells, such as electrical stimulation, are not cell-specific. Optogenetics is. You can target one cell type without disturbing others. That gives unprecedented precision for understanding and treating brain disorders.

The research has already led to experimental treatments for blindness. In patients with degeneration of photoreceptor cells, light-sensitive proteins were introduced into surviving retinal cells, enabling some degree of light perception. Optogenetics is also being explored for Alzheimer’s disease, though those applications remain in early clinical stages.

Relevance for brain aging

For brain aging and neurodegeneration, optogenetics matters in two ways. First, as a research tool: it lets scientists identify exactly which cell types and circuits are involved in memory decline and other age-related changes. Second, as a potential treatment platform that could recalibrate specific brain circuits.

The translation from mouse models to clinical treatment remains a large step for most brain conditions. But the Nobel Prize recognizes that optogenetics has made a transformative contribution to neuroscience, and human applications are growing.

Read the original article